Search

Displaying results 1521 - 1530 of 6076 in total
  1. Drug

    Hydroxyurea

    go.drugbank.com/drugs/DB01005
    ApprovedInvestigational

    [A262596] It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. … A262601] Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, hydroxyurea is used sparingly in clinical settings, largely due to lack of knowledge and adherence, the need for

  2. Drug

    Icosapent

    go.drugbank.com/drugs/DB00159
    ApprovedInvestigationalNutraceutical

    It serves as the precursor for the prostaglandin-3 and thromboxane-3 families.

  3. Drug

    Meningococcal polysaccharide vaccine group C

    go.drugbank.com/drugs/DB13890
    ApprovedInvestigational

    Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from Neisseria meningitidis serogroup C. N. meningitidis is a bacteria that causes endemic and epidemic diseases including meningitis a...

    Mixtures: MENVEO POWDER & SOLUTION FOR SOLUTION FOR INJECTION, Menveo Powder and Solution for Solution for Injection
  4. Drug

    Meningococcal polysaccharide vaccine group W-135

    go.drugbank.com/drugs/DB13887
    ApprovedInvestigational

    Meningococcal group W-135 polysaccharide is group-specific polysaccharide antigens extracted and purified from Neisseria meningitidis serogroup W-135. N. meningitidis is a bacteria that causes endemic and epidemic diseases including meni...

    Mixtures: MENVEO POWDER & SOLUTION FOR SOLUTION FOR INJECTION, Menveo Powder and Solution for Solution for Injection
  5. Drug

    Tiludronic acid

    go.drugbank.com/drugs/DB01133
    ApprovedVet approvedWithdrawn

    [A1923] Tiludronic acid was first described in the literature in 1988 as a potential treatment for Paget's disease of bone.[A202235] Tiludronic acid was granted FDA approval on 7 March 1997.[L4763]

    Categories: Drugs for Treatment of Bone Diseases
  6. Drug

    Avacopan

    go.drugbank.com/drugs/DB15011
    ApprovedInvestigational

    [A240254, A240259, A240264, A240269] Avacopan (formerly CCX168) is an allosteric C5aR antagonist indicated for use in AAV. … [L38919] On January 19, 2022, the European Commission approved avacopan for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA) - the

  7. Drug

    Becaplermin

    go.drugbank.com/drugs/DB00102
    ApprovedInvestigational

    Becaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae.

    Categories: Preparations for Treatment of Wounds and Ulcers
  8. Drug

    Nitrous acid

    go.drugbank.com/drugs/DB09112
    ApprovedInvestigational

    There is also research to investigate its applicability towards treatments for heart attacks, brain aneurysms, pulmonary hypertension in infants, and Pseudomonas aeruginosa infections.

  9. Drug

    Ethynodiol diacetate

    go.drugbank.com/drugs/DB00823
    Approved

    Although etynodiol or ethynodiol are sometimes used as a synonym for ethynodiol diacetate, what is usually being referred to is actually ethynodiol diacetate and not ethynodiol (which is a separate drug

    Categories: Hormonal Contraceptives for Systemic Use
  10. Drug

    Concizumab

    go.drugbank.com/drugs/DB12820
    ApprovedInvestigational

    [L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors. … Concizumab therefore provides an important treatment option for patients who have developed inhibitors to standard clotting factor replacement therapy.